AR013422A1 - UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA - Google Patents

UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA

Info

Publication number
AR013422A1
AR013422A1 ARP980104054A ARP980104054A AR013422A1 AR 013422 A1 AR013422 A1 AR 013422A1 AR P980104054 A ARP980104054 A AR P980104054A AR P980104054 A ARP980104054 A AR P980104054A AR 013422 A1 AR013422 A1 AR 013422A1
Authority
AR
Argentina
Prior art keywords
propute
polypeptide
lead
nucleic acid
complete
Prior art date
Application number
ARP980104054A
Other languages
English (en)
Spanish (es)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR013422A1 publication Critical patent/AR013422A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
ARP980104054A 1997-08-14 1998-08-14 UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA AR013422A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use

Publications (1)

Publication Number Publication Date
AR013422A1 true AR013422A1 (es) 2000-12-27

Family

ID=27517687

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980104054A AR013422A1 (es) 1997-08-14 1998-08-14 UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
ARP070104104A AR062867A2 (es) 1997-08-14 2007-09-17 Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070104104A AR062867A2 (es) 1997-08-14 2007-09-17 Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la

Country Status (28)

Country Link
US (4) US6605280B1 (cg-RX-API-DMAC7.html)
EP (1) EP1003781B1 (cg-RX-API-DMAC7.html)
JP (1) JP4272348B2 (cg-RX-API-DMAC7.html)
KR (1) KR100687388B1 (cg-RX-API-DMAC7.html)
CN (1) CN1243021C (cg-RX-API-DMAC7.html)
AR (2) AR013422A1 (cg-RX-API-DMAC7.html)
AT (1) ATE443719T1 (cg-RX-API-DMAC7.html)
AU (1) AU755794B2 (cg-RX-API-DMAC7.html)
BG (1) BG65519B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI9811940B8 (cg-RX-API-DMAC7.html)
CA (1) CA2298855C (cg-RX-API-DMAC7.html)
CY (1) CY1109664T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ300818B6 (cg-RX-API-DMAC7.html)
DE (2) DE1003781T1 (cg-RX-API-DMAC7.html)
DK (1) DK1003781T3 (cg-RX-API-DMAC7.html)
EA (1) EA003675B1 (cg-RX-API-DMAC7.html)
EE (1) EE05538B1 (cg-RX-API-DMAC7.html)
ES (1) ES2149149T3 (cg-RX-API-DMAC7.html)
HU (1) HU226698B1 (cg-RX-API-DMAC7.html)
IL (5) IL121860A0 (cg-RX-API-DMAC7.html)
NO (1) NO327240B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ502392A (cg-RX-API-DMAC7.html)
PL (1) PL206070B1 (cg-RX-API-DMAC7.html)
PT (1) PT1003781E (cg-RX-API-DMAC7.html)
SI (1) SI1003781T1 (cg-RX-API-DMAC7.html)
SK (1) SK287194B6 (cg-RX-API-DMAC7.html)
UA (1) UA75862C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999009063A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
CA2324168A1 (en) * 1999-11-16 2001-05-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
EP2332579A3 (en) * 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
IL151388A0 (en) * 2000-02-21 2003-04-10 Applied Research Systems Use of il-18 inhibitors
CA2407895C (en) * 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002031115A2 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2295332T3 (es) * 2001-01-29 2008-04-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias.
CN100556450C (zh) * 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
US7655616B2 (en) * 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
NO345566B1 (no) 2001-06-26 2021-04-19 Amgen Inc OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
ES2314191T3 (es) * 2002-03-22 2009-03-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas.
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
EP1572291B1 (en) * 2002-10-08 2013-04-03 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
CN100457901C (zh) * 2003-04-30 2009-02-04 独立行政法人科学技术振兴机构 人抗人白介素-18抗体及其片断和它们的利用方法
PT1622939E (pt) * 2003-05-13 2012-03-28 Merck Serono Sa Variantes ativas da proteína de ligação à il-18 e suas utilizações médicas
ES2285543T3 (es) 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CN101018808B (zh) 2003-11-12 2014-07-23 科罗拉多州大学评议会 调节肿瘤坏死因子α的组合物和方法
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
EP1720979B1 (en) * 2004-03-01 2007-10-10 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
WO2006003134A1 (en) * 2004-06-29 2006-01-12 Ares Trading S.A. Process for the purification of il-18 binding protein
PL1888100T3 (pl) * 2005-06-03 2012-03-30 Merck Serono Sa Zastosowanie lizoform IL-18BP do leczenia i/lub zapobiegania neurologicznym chorobom zapalnym
SI2267024T1 (sl) * 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
RS52273B (sr) * 2005-06-10 2012-10-31 Ares Trading S.A. Proces za purifikaciju il-18 vezujućeg proteina
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
EA017303B1 (ru) 2006-05-25 2012-11-30 Глаксо Груп Лимитед Модифицированные гуманизированные антитела против интерлейкина-18 и их применение
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US20150352561A1 (en) * 2013-01-02 2015-12-10 Wilsa Holdings ,LLC Method and Apparatus for Conditioning Fluids
KR102512797B1 (ko) 2013-09-05 2023-03-22 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
EP3265807A1 (en) 2015-03-05 2018-01-10 AB2 Bio SA Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN117279950B (zh) * 2022-01-28 2025-08-08 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
EP4493195A1 (en) * 2022-03-15 2025-01-22 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
CN120530131A (zh) 2023-01-06 2025-08-22 拉森医疗公司 抗il-18bp抗体
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
SI20110A (sl) 1997-03-18 2000-06-30 Basf Aktiengesellschaft Metode in sestavki za moduliranje odzivnosti na kortikosteroide
DE69834727T2 (de) 1997-08-01 2007-01-25 Serono Genetics Institute S.A. 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
JP2001512012A (ja) 1997-08-01 2001-08-21 ジェンセット 精巣およびその他の組織で発現する分泌タンパク質の５’ｅｓｔ
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
TR200101751T2 (tr) 1998-04-28 2002-05-21 Applied Research Systems Ars Holding N.V. Poliol-IFN-beta konjugatları
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
CZ2000490A3 (cs) 2000-08-16
DK1003781T3 (da) 2010-01-25
PT1003781E (pt) 2009-10-26
JP4272348B2 (ja) 2009-06-03
US6605280B1 (en) 2003-08-12
NO327240B1 (no) 2009-05-18
CN1267307A (zh) 2000-09-20
HK1028773A1 (en) 2001-03-02
EE05538B1 (et) 2012-04-16
NO20000700D0 (no) 2000-02-11
UA75862C2 (uk) 2006-06-15
BRPI9811940A (pt) 2000-09-05
ES2149149T3 (es) 2009-12-01
HU226698B1 (en) 2009-07-28
EA200000216A1 (ru) 2000-08-28
DE69841175D1 (de) 2009-11-05
JP2001514876A (ja) 2001-09-18
BRPI9811940B8 (pt) 2021-07-06
PL338647A1 (en) 2000-11-06
DE1003781T1 (de) 2001-01-11
ES2149149T1 (es) 2000-11-01
KR100687388B1 (ko) 2007-02-26
CY1109664T1 (el) 2014-08-13
US8436148B2 (en) 2013-05-07
AU8746098A (en) 1999-03-08
IL125463A0 (en) 1999-03-12
EE200000073A (cg-RX-API-DMAC7.html) 2000-10-16
WO1999009063A1 (en) 1999-02-25
IL134523A (en) 2011-09-27
IL122134A0 (en) 1998-04-05
BRPI9811940B1 (pt) 2011-10-04
EP1003781B1 (en) 2009-09-23
HUP0003533A2 (hu) 2001-01-29
AR062867A2 (es) 2008-12-10
BG65519B1 (bg) 2008-10-31
CA2298855A1 (en) 1999-02-25
CN1243021C (zh) 2006-02-22
CZ300818B6 (cs) 2009-08-19
US20040037829A1 (en) 2004-02-26
SK287194B6 (sk) 2010-03-08
BG104149A (bg) 2000-08-31
IL121860A0 (en) 1998-02-22
HUP0003533A3 (en) 2003-08-28
NZ502392A (en) 2002-12-20
EP1003781A1 (en) 2000-05-31
NO20000700L (no) 2000-04-14
SI1003781T1 (sl) 2009-12-31
US7799541B2 (en) 2010-09-21
ATE443719T1 (de) 2009-10-15
US20100010200A1 (en) 2010-01-14
US20060154294A1 (en) 2006-07-13
KR20010022900A (ko) 2001-03-26
SK1762000A3 (en) 2000-09-12
IL134523A0 (en) 2001-04-30
AU755794B2 (en) 2002-12-19
EA003675B1 (ru) 2003-08-28
CA2298855C (en) 2014-05-27
US7101689B2 (en) 2006-09-05
PL206070B1 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
AR013422A1 (es) UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
UA42760C2 (uk) Спосіб спрямування клітинної імунної відповіді проти віл-інфікованої клітини ссавця,білковий мембранозв'язаний химерний рецептор,днк,яка кодує химерний рецептор,вектор,що її містить
BG101171A (en) Antibodies which bind to insect gut proteins and their use
DE69324359D1 (de) Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
NZ503343A (en) Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
ATE353362T1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
ATE449109T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
ES508813A0 (es) Metodo de expresion de un gen codificador de un polipeptido util en una coagulacion de la leche.
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
ATE313633T1 (de) Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren
DK13788D0 (da) Fremgangsmaade til fremstilling af et polypeptid
ATE353365T1 (de) Neue b7-4 moleküle und deren verwendungen
MX428A (es) Region regulatoria para expresion de gen heterologa en levadura.
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
MXPA01002592A (es) Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
DK111183A (da) Polypeptid omfattende aminosyresekvensen af et dyreinterferon, dna-sekvens, der koder for polypeptidet, replicerbart udtrykkelsesmedium, som kan udtrykke dna-sekvensen, og fremgangsmaade til fremstilling af polypeptidet
NO860421L (no) Sammensmeltet gen som koder for et hybridprotein.
ATE353964T1 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
ES2170051T3 (es) Procedimiento para la produccion de proteinas utilizando proteinas fusionadas de tipo cks.
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
ES2120409T3 (es) Nuevos vectores de expresion y metodos para la produccion de proteinas intracelulares.

Legal Events

Date Code Title Description
FG Grant, registration